Download PDF
Am J Perinatol
DOI: 10.1055/s-0044-1789018
Original Article

Impact of the ARRIVE Trial on Stillbirth Rates in Nulliparous Individuals

Rula Atwani
1   Department of Obstetrics and Gynecology, Macon & Joan Brock Virginia Health Sciences at Old Dominion University, Norfolk, Virginia
,
George Saade
1   Department of Obstetrics and Gynecology, Macon & Joan Brock Virginia Health Sciences at Old Dominion University, Norfolk, Virginia
,
Tetsuya Kawakita
1   Department of Obstetrics and Gynecology, Macon & Joan Brock Virginia Health Sciences at Old Dominion University, Norfolk, Virginia
› Author Affiliations Funding None.
› Further Information
Also available at
    Permissions and Reprints

Abstract

Objective We aim to examine the population-level rates of induction, stillbirth, perinatal mortality, and neonatal death before and after the ARRIVE (A Randomized Trial of Induction Versus Expectant Management) trial.

Study Design This study was a cross-sectional analysis of publicly available U.S. Live Birth data linked with Infant Death and Fetal Death certificate data from National Vital Statistics Online. We limited analyses to nulliparous individuals with singleton pregnancy and cephalic presentation who delivered at 39 weeks or greater. The pre- and post-ARRIVE periods spanned from August 2016 to July 2018, and from January 2019 to December 2020, respectively. Our primary outcome was a stillbirth. Secondary outcomes included induction of labor, perinatal mortality, and neonatal death. Outcomes were compared between the pre- and post-ARRIVE periods. Modified Poisson regression was used to calculate adjusted relative risks (aRRs).

Results Of 2,817,071 births, there were 1,454,346 births in the pre-ARRIVE period and 1,362,725 in the post-ARRIVE period; there were 1,196 and 1,062 stillbirths in the pre- and post-ARRIVE periods, respectively. Compared to the pre-ARRIVE period, the post-ARRIVE period was not associated with a significant decrease in the risk of stillbirth at 39 weeks or greater (aRR 0.92 [95% confidence interval {95% CI} 0.85–1.00]) and stillbirth at 40 weeks or greater (aRR 0.92 [95% CI 0.82–1.04]). Compared to the pre-ARRIVE trial period, the post-ARRIVE trial was associated with increased rates of induction of labor at 39 weeks (aRR 1.37 [95% CI 1.37–1.38]) and 40 weeks (aRR 1.24 [95% CI 1.24–1.25]. Similar to stillbirth, there was no significant decrease in the risk of perinatal mortality at 39 weeks or greater or 40 weeks or greater. There was also no statistically significant change in neonatal death rates at 39 weeks or greater or at 40 weeks or greater.

Conclusion The increase in induction of labor at 39 weeks was not large enough to impact the stillbirth rate at 39 weeks or greater.

Key Points

  • Post-ARRIVE trial, rate of induction of labor increased at 39 and 40 weeks.

  • Post-ARRIVE trial, stillbirth and perinatal mortality rates remained unchanged.

  • Induction rate rise post-ARRIVE trial did not impact neonatal death rates.

Keywords

induction of labor - neonatal death - perinatal mortality

Supplementary Material



Publication History

Received: 12 July 2024

Accepted: 25 July 2024

Article published online:
13 August 2024

© 2024. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Grobman WA, Rice MM, Reddy UM. et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal–Fetal Medicine Units Network. Labor induction versus expectant management in low-risk nulliparous women. N Engl J Med 2018; 379 (06) 513-523
    CrossrefPubMedGoogle Scholar
  • 2 Ghartey J, Macones GA. 39-week nulliparous inductions are not elective. Am J Obstet Gynecol 2020; 222 (06) 519-520
    CrossrefPubMedGoogle Scholar
  • 3 Berghella V, Al-Hafez L, Bellussi F. Induction for 39 weeks' gestation: let's call it what it is. Am J Obstet Gynecol MFM 2020; 2 (02) 100098
    CrossrefPubMedGoogle Scholar
  • 4 Gilroy LC, Al-Kouatly HB, Minkoff HL, McLaren Jr RA. Changes in obstetrical practices and pregnancy outcomes following the ARRIVE trial. Am J Obstet Gynecol 2022; 226 (05) 716.e1-716.e12
    CrossrefPubMedGoogle Scholar
  • 5 Nethery E, Levy B, McLean K, Sitcov K, Souter VL. Effects of the ARRIVE (A Randomized Trial of Induction Versus Expectant Management) Trial on elective induction and obstetric outcomes in term nulliparous patients. Obstet Gynecol 2023; 142 (02) 242-250
    CrossrefPubMedGoogle Scholar
  • 6 Gregory EC, Valenzuela CP, Hoyert DL. Fetal mortality: United States, 2020. Natl Vital Stat Rep 2022; 71 (04) 1-20
    PubMedGoogle Scholar
  • 7 Gardosi J, Madurasinghe V, Williams M, Malik A, Francis A. Maternal and fetal risk factors for stillbirth: population based study. BMJ 2013; 346: f108-f108
    CrossrefPubMedGoogle Scholar
  • 8 American College of Obstetricians and Gynecologists. Management of stillbirth: Obstetric Care Consensus No, 10. Obstet Gynecol 2020; 135 (03) e110-e132
    CrossrefPubMedGoogle Scholar
  • 9 Flenady V, Wojcieszek AM, Middleton P. et al; Lancet Ending Preventable Stillbirths study group, Lancet Stillbirths In High-Income Countries Investigator Group. Stillbirths: recall to action in high-income countries. Lancet 2016; 387 (10019): 691-702
    CrossrefPubMedGoogle Scholar
  • 10 Rosenstein MG, Cheng YW, Snowden JM, Nicholson JM, Caughey AB. Risk of stillbirth and infant death stratified by gestational age. Obstet Gynecol 2012; 120 (01) 76-82
    CrossrefPubMedGoogle Scholar
  • 11 Peleg D, Warsof SL. The impact of induction of labor at 39 weeks on the incidence of stillbirth in low-risk women. Am J Obstet Gynecol 2020; 223 (01) 139-140
    CrossrefPubMedGoogle Scholar
  • 12 Centers for Disease Control and Prevention. User Guide to the 2021 Natality Public Use File. 2022 . Accessed September 6, 2023 at: https://ftp.cdc.gov/pub/Health_Statistics/NCHS/Dataset_Documentation/DVS/natality/UserGuide2021.pdf
    PubMedGoogle Scholar
  • 13 Centers for Disease Control and Prevention. National Vital Statistics System. Birth Data. Accessed September 6, 2023 at: https://www.cdc.gov/nchs/nvss/births.htm
    PubMedGoogle Scholar
  • 14 Centers for Disease Control and Prevention. Attachment to the Facility Worksheet for the Live Birth Certificate for Multiple Births. 2016 . Accessed September 6, 2023 at: https://www.cdc.gov/nchs/data/dvs/multiple-births-worksheet-2016.pdf
    PubMedGoogle Scholar
  • 15 American College of Obstetricians and Gynecologists. Clinical Guidance for Integration of the Findings of The ARRIVE Trial: labor induction versus expectant management in low-risk nulliparous women. 2018 . Accessed July 31, 2024 at: https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2018/08/clinical-guidance-for-integration-of-the-findings-of-the-arrive-trial
    PubMedGoogle Scholar
  • 16 Society of Maternal-Fetal (SMFM) Publications Committee. Electronic address: pubs@smfm.org. SMFM Statement on elective induction of labor in low-risk nulliparous women at term: the ARRIVE Trial. Am J Obstet Gynecol 2019; 221 (01) B2-B4
    CrossrefPubMedGoogle Scholar
  • 17 Yudkin PL, Wood L, Redman CWG. Risk of unexplained stillbirth at different gestational ages. Lancet 1987; 1 (8543) 1192-1194
    CrossrefPubMedGoogle Scholar
  • 18 MacDorman MF, Reddy UM, Silver RM. Trends in stillbirth by gestational age in the United States, 2006-2012. Obstet Gynecol 2015; 126 (06) 1146-1150
    CrossrefPubMedGoogle Scholar
  • 19 Caughey AB. Measuring perinatal complications: methodologic issues related to gestational age. BMC Pregnancy Childbirth 2007; 7 (01) 18
    CrossrefPubMedGoogle Scholar
  • 20 Muglu J, Rather H, Arroyo-Manzano D. et al. Risks of stillbirth and neonatal death with advancing gestation at term: a systematic review and meta-analysis of cohort studies of 15 million pregnancies. PLoS Med 2019; 16 (07) e1002838
    CrossrefPubMedGoogle Scholar
  • 21 Zou G. A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol 2004; 159 (07) 702-706
    CrossrefPubMedGoogle Scholar
  • 22 Centers for Disease Control and Prevention. COVID Data Tracker. Atlanta, GA: U.S. Department of Health and Human Services. Accessed July 31, 2024 at: https://covid.cdc.gov/covid-data-tracker
    PubMedGoogle Scholar
  • 23 Sinkey RG, Lacevic J, Reljic T. et al. Elective induction of labor at 39 weeks among nulliparous women: the impact on maternal and neonatal risk. PLoS ONE 2018; 13 (04) e0193169
    CrossrefPubMedGoogle Scholar
  • 24 DeSisto CL, Wallace B, Simeone RM. et al. Risk for stillbirth among women with and without COVID-19 at delivery hospitalization - United States, March 2020-September 2021. MMWR Morb Mortal Wkly Rep 2021; 70 (47) 1640-1645
    CrossrefPubMedGoogle Scholar
  • 25 Ota E, da Silva Lopes K, Middleton P. et al. Antenatal interventions for preventing stillbirth, fetal loss and perinatal death: an overview of Cochrane systematic reviews. Cochrane Database Syst Rev 2020; 12 (12) CD009599
    PubMedGoogle Scholar
  • 26 Atkins B, Kindinger L, Mahindra MP, Moatti Z, Siassakos D. Stillbirth: prevention and supportive bereavement care. BMJ Med 2023; 2 (01) e000262
    CrossrefPubMedGoogle Scholar
  • 27 Gilroy L, Al-Kouatly HB, Minkoff H, McLaren R. Trends in early term induction and delivery among low-risk nulliparas after the ARRIVE publication. Am J Obstet Gynecol 2023; 228 (01) S31-S32
    CrossrefPubMedGoogle Scholar
  • 28 Souter V, Nethery E, Levy B, Mclean K, Sitcov K. Elective induction of labor in nulliparas: has the ARRIVE trial changed obstetric practices and outcomes?. Am J Obstet Gynecol 2022; 226 (01) S83-S84
    CrossrefPubMedGoogle Scholar
  • 29 Wood R, Freret TS, Clapp M, Little S. Rates of induction of labor at 39 weeks and cesarean delivery following publication of the ARRIVE Trial. JAMA Netw Open 2023; 6 (08) e2328274
    CrossrefPubMedGoogle Scholar